Last reviewed · How we verify

NCT05505123

Sevoflurane and Propofol for Botulinum Toxin Injection

Withdrawn NA Last updated 15 February 2023
What this trial tests

NA trial testing Sevoflurane in Cerebral Palsy. Withdrawn.

Timeline
26 August 2022
Primary endpoint
9 December 2022
9 December 2022

Quick facts

Lead sponsorYeungnam University College of Medicine
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Start date26 August 2022
Primary completion9 December 2022
Estimated completion9 December 2022
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Yeungnam University College of Medicine

Who can join

Adults 3 to 11, any sex, with Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators would like to compare clinical features (onset, duration, emergence time), efficacy of deep sedation (successful completion of procedure), safety (adverse events) and caregiver's satisfaction for sedation when used propofol and sevoluflurane for deep sedation in 3-11 year old pediatric patients with spastic cerebral palsy receiving botulinum toxin injection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sevoflurane

Trials testing the same drug.

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other Yeungnam University College of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05505123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing